Event Calendar
Find out what's happening in the area of Horizon Europe, Digital Europe and Horizon 2020
EIT InnoEnergy: The Business Booster
The Business Booster is EIT InnoEnergy's annual two day international networking event that showcases over 150 sustainable energy technologies under one roof. Each year, the event rotates among European cities, bringing together industry leaders, investors, policy makers and entrepreneurs. In October 2024, the Business Booster welcomes participants in the city of Barcelona to explore latest trends in sustainable energy innovation.
Pre-registration for the event is open now until 31 March 2024. Stakeholders who pre-register will receive a 50% discount code, applicable for one week only from 1-8 April.
More information on the event's webpage. Note that this is a paying event.
myOVERVIEW
-
sign up for personalised information
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Event calendar
24 upcoming events view event calendarSecurity AI, data & cloud Cybersecurity Defence Space
Info day on the DEFRA call 2025
Testimonial
BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment
The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.
